Say good things about our drugs and get paid

Scientists, MD's and Psych's

Lori Altshuler, M.D., Professor of Psychiatry, Director, UCLA Mood Disorders Research Program

WHAT SHE WANTS YOU TO KNOW:

Dr. Altshuler holds the Julia S. Gouw Endowed Chair for Mood Disorders. She received her bachelor and M.D. degrees from Cornell University. Following completion of her residency at the UCLA Neuropsychiatric Institute, she conducted research as a visiting scholar at the Shanghai Psychiatric Institute in Shanghai, China. Upon her return, she continued her research in the biological correlates of schizophrenia and bipolar disorder during a two-year fellowship at the Biological Psychiatry branch of the NIMH. In 1989, Dr. Altshuler was appointed assistant clinical professor at the UCLA Neuropsychiatric Institute, and in her first year on faculty she received the UCLA Neuropsychiatric Hospital Junior Faculty Distinguished Teaching Award. She has been an active teacher and mentor, and in 1994 and 2004 she received the UCLA Department of Psychiatry Outstanding Research Mentor Award. She has also been recognized for her research by the National Alliance for the Mentally Ill (1996 Judith Silver Young Scientist Award) and the National Depressive, Manic-Depressive Association (1997 Gerald L. Klerman Young Investigator Award. Dr. Altshuler directs two research programs: the UCLA Mood Disorders Research Program and the Women’s Research Program.

WHAT SHE WOULD PREFER YOU DIDN'T KNOW

Lori Altshuler, M.D., Professor and Director, Mood Disorders Research Program, University of California, Los Angeles.

Grants/research support from Abbott Laboratories, Eli Lilly, Forest Labs, Glaxo-Wellcome, SmithKlineBeecham, and Solvay. Consultant to Abbott Laboratories, Eli Lilly, Forest Labs, Janssen, Parke Davis, and Bristol Myers Squibb. Member,speakers bureaus of Abbott Laboratories, Eli Lilly, Glaxo-Wellcome, and Solvay. Scientfic Advisory Board for Abbott Laboratories, Eli Lilly, and Forest Labs. (Conference disclosure notes: 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI; Primary Care Companion J Clin Psychiatry. 2000; 2:217-23)



----

Dr David Baldwin, School of Medicine, University of Southampton

WHAT HE WANTS YOU TO KNOW

Dr David Baldwin, Senior Lecturer in Psychiatry, has recently joined the Division and he continues his studies into the causes and associations of anxiety and depression, and the use of pharmacological agents in the treatment of anxiety and depressive disorders.

WHAT HE WOULD PREFER YOU DIDN'T KNOW

David Baldwin, M.R.C.Psych., Senior Lecturer in Psychiatry, Southampton University, UK.

Member of the advisory board of Wyeth. (Psychopharmacol. Bull. 2002: 36 Suppl. 2;158-65) Member of the Bristol Myers Squibb study group on CN-104-070 (nefazodone). (J. Psychopharmacol. 2001:15(3);161-5) According to the Guardian, while providing expert testimony at the Committee for Safety of Medicine’s review of the side effects of Seroxat (Paxil), Prozac, and other antidepressants, “[Dr. Baldwin] declared a personal interest in Lundbeck, manufacturers of the drug Citalopram. According to the minutes, however, he did not declare his connections with five other [pharmaceutical] companies, including Seroxat manufacturers SmithKline Beecham, which is now GlaxoSmithKline. [When] questioned by the Guardian…he did declare participating in the advisory boards for SmithKline Beecham, Bristol-Myers Squibb, Eli Lilly, Organon, and Pharmacia…[and] had been paid for speaking at symposia to other doctors about [their] drugs.” (The Guardian, 3/17/03)

----

David L. Dunner, MD Professor, Department of Psychiatry, University of Washington

WHAT HE WANTS YOU TO KNOW

David Dunner, MD, attended Washington University School of Medicine and completed his psychiatric training there. He spend two years at the National Institute of Mental Health involved in research studies in bipolar depression. For the next eight years he was at Columbia University/New York State Psychiatric Institute and worked with Dr. Ronald Fieve on studies comparing bipolar and unipolar affective disorders. These studies included clinical descriptive studies, family studies, biological studies, and treatment outcome studies.

WHAT HE WOULD PREFER YOU DIDN'T KNOW

Research on the effectiveness of St. John's Wort in major depression supported in part by Pfizer. (JAMA 2001;285:1978-86) Co-authored a 1995 paper on Seroxat (Paxil) sponsored by GlaxoSmithKline and co-authored by a Glaxo employee. According to the Tacoma News Tribune, Dr. Dunner "consulted for Bristol-Myers Squibb, SmithKline Beecham (now GlaxoSmithKline), Glaxo Wellcome, and Eli Lilly. He received research grants from Bristol-Myers Squibb, Pfizer, Pharmacia-Upjohn, SmithKline Beecham, Forest Laboratories, Glaxo Wellcome, and Wyeth-Ayerst. He earned speaking fees from Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, Eli Lilly, Organon, and Wyeth-Ayerst . . . In a 1994 deposition for a lawsuit involving Prozac, [Dr.] Dunner said he earned $2,000 for each advisory board meeting he attended for Eli Lilly - a typical honorarium. The board met twice a year . . . Since the 1998-9 academic year, Dunner has filed [with the university] at least 60 requests to work for drug companies." (Tacoma News Tribune, 10/13/02, p. A1)


MORE COMING SOON